Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine

This is a cohort study performed in patients with cardiovascular diaeases who were treated with oral Chinese medicine and Western medicine. Collect indicators such as the incidence of cardiovascular events, all due to readmission, all due to death. To hospital using clinical samples to detect genomics, proteomics, metabolomics, intestinal flora and sclerotia.To explore the clinical efficacy of Chinese patent medicine in the treatment of cardiovascular diseases, and provide reliable data support for its clinical application.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiovascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Tianjin University of Traditional Chinese Medicine

Tianjin, China

Location status: Recruiting

Location contact

Lin Li, Master

CONTACT

[email protected]

+8613820396963

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients admitted to the Department of Cardiovascular Medicine at The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, The Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Chest Hospital, Tianjin Hospital of ITCWM Nankai Hospital and Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital were considered for inclusion in this study, and all Western medical diagnoses were identified and classified according to the International Classification of Diseases, 11th Revision (ICD-11).

Exclusion criteria

No exclusion criteria.

Treatment and study plan

Chinese patent medicine

Drug

Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.

Primary outcomes

Cardiovascular Events Cardiovascular Events Cardiovascular Events

Time frame: one year

Non-fatal myocardial infarction, non-fatal ischemic stroke, unplanned hemodynamic reconstruction.
All due to readmission

Time frame: one year

Readmission for cardiovascular events and readmission for other reasons.
All due to death

Time frame: one year

Cardiac death and death from other causes.

Sponsors and collaborators

Lead sponsor

Tianjin University of Traditional Chinese Medicine

Other

Registry information

Acronym: CSCD-TCM plus

Important dates

Study start: 2021
Primary completion: 2024
Study completion: 2031
First posted: Apr 4, 2022
Registry last updated: Apr 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting